Genfit and LabCorp’s drug development business Covance have signed a licensing agreement that will expand access to a new diagnostic test for Non-Alcoholic Steatohepatitis (NASH).

NASH is an asymptomatic disease which often advances to life-threatening stages before clinical diagnosis. An invasive procedure, a liver biopsy is currently a standard process to diagnose NASH and stage fibrosis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Through the agreement, the two companies aim to offer the clinical research community a non-invasive test to detect and monitor patients with NASH and significant fibrosis.

“The test utilises a biobank of samples from nearly 700 well-characterised patients to form a novel combination of biomarkers to detect patients with NASH and significant fibrosis.”

Genfit has already developed a non-invasive multi-parametric blood-based biomarker test called NIS4.

The test utilises a biobank of samples from nearly 700 well-characterised patients to form a novel combination of biomarkers to detect patients with NASH and significant fibrosis.

Under the licensing agreement, the new NASH diagnostic test will be deployed in the clinical research space through Covance’s central laboratories for further validation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The process is also expected to generate new biological insights into NASH disease pathogenesis.

Genfit chairman and CEO Jean-François Mouney said: “We are very enthusiastic to announce this agreement, which represents a major step in GENFIT’s commercial strategy in NASH.

“The expertise that LabCorp and Covance have in this field will add tremendous value to Genfit’s pioneering work in developing this innovative technology.

“I’m excited to see collaborations like this, which will help move the test toward the goal of being an in vitro diagnostic (IVD) to identify NASH patients who should be considered for therapeutic intervention.”

The companies have not disclosed the financial terms of the agreement.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact